Former Biogen R&D Chief Surfaces With Exosome-Focused Startup
This article was originally published in Scrip
Douglas Williams turned heads in July when Biogen revealed that its executive vice president leading research and development was leaving to found a biotechnology startup, and now Williams has emerged from the fundraising process as the president and CEO of Codiak BioSciences with venture capital to develop exosomes-based therapeutics and diagnostics.
You may also be interested in...
Semma closed a $114m Series B round to fund development of insulin-producing cells. Also, Tesaro and Catalyst are among recent public company financings, while Otonomy shifted gears, laying off sales staff.
Bristol became a major hematology player through its acquisition of Celgene and it has a multi-pronged plan for maintaining its position as generics approach for Revlimid and other key products.
The company will seek US FDA approval after intranasally administered zavegepant passes its second pivotal test in the treatment of migraine attacks, followed by ex-US approvals with partner Pfizer.